Cardiac safety of liposomal anthracyclines.

@article{Ewer2004CardiacSO,
  title={Cardiac safety of liposomal anthracyclines.},
  author={Michael S. Ewer and Francis J. O. Martin and Craig Darren Mark Henderson and Charles L. Shapiro and Robert S Benjamin and Alberto Gabizon},
  journal={Seminars in oncology},
  year={2004},
  volume={31 6 Suppl 13},
  pages={
          161-81
        }
}
Conventional anthracyclines are active against many tumor types, but cardiotoxicity related to the cumulative dose may limit their use; this is particularly problematic for patients with risk factors for increased toxicity, for those who have received any anthracycline in the past, or for those who are to receive other cardiotoxic agents. Preclinical studies determined that encapsulating conventional anthracyclines in liposomes reduced the incidence and severity of cumulative dose-related… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Similar Papers

Loading similar papers…